The European Medicines Agency is aware that its US counterpart, the Food and Drug Administration, offers a “much higher variety” of early support mechanisms for sponsors, but it is aiming to support companies as much as it can, according to the head of the agency’s scientific advisory office, Iordanis Gravanis.
EMA ‘Trying Its Best’ To Offer More Early Scientific Support For Sponsors
The head of the European Medicines Agency’s scientific advisory office is hopeful that the organization’s PRIME initiative will be enshrined in EU legislation over the coming years, rather than just existing as an initiative from the agency.
More from Rare Diseases
More from Pink Sheet
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.